drugset / Trial / NCT00379041

Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

NCT00379041 ↗

Phase 3 Active not recruiting 1158 enrolled European Organisation for Research and Treatment of Cancer - EORTC
RandomizedTreatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with combination chemotherapy may kill more cancer cells. It is not yet known whether radiation therapy is more effective with or without combination chemotherapy in treating patients with Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works with or without combination chemotherapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma.

Timeline

Start
1993-09-01
Primary completion
1998-10-01
Completion
—

Outcome

Met primary endpoint

paper event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). PMID 17989384 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bleomycin Unknown — Intramuscular
Subject Doxorubicin Other / unclassified — Intravenous
Subject Prednisone Other / unclassified — Oral
Subject Vinblastine Small molecule — Intravenous
Subject Vincristine Small molecule — Intravenous
Subject mechlorethamine Small molecule — Intravenous
Subject procarbazine Small molecule — Oral

Indications